High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.

Ann Hematol · 2018 · PMC6097751 · PMID 29946907

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

at the limit of significancep = 0.06so close (0.05 < p ≤ 0.1)

In the control group (CTD non-responders), the analysis showed only a modest increase in the activity and concentration at the end of therapy compared to their baseline values, standing at the limit of significance ( p = 0.06 for both respectively) (Figs. 1 and 2 d and Table 2 ).

also in 326 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.